Cullinan Therapeutics CGEM Stock
Cullinan Therapeutics Price Chart
Cullinan Therapeutics CGEM Financial and Trading Overview
| Cullinan Therapeutics stock price | 17.15 USD |
| Previous Close | 15.51 USD |
| Open | 15.58 USD |
| Bid | 11.67 USD x 200 |
| Ask | 19.52 USD x 200 |
| Day's Range | 15.13 - 16.54 USD |
| 52 Week Range | 5.71 - 23.19 USD |
| Volume | 1.08M USD |
| Avg. Volume | 842.91K USD |
| Market Cap | 1.03B USD |
| Beta (5Y Monthly) | -0.041 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.11 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.45 USD |
CGEM Valuation Measures
| Enterprise Value | 699.78M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.838779 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.2080002 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -3.159 |
Trading Information
Cullinan Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.041 |
| 52-Week Change | 165.58% |
| S&P500 52-Week Change | 14.57% |
| 52 Week High | 23.19 USD |
| 52 Week Low | 5.71 USD |
| 50-Day Moving Average | 19.43 USD |
| 200-Day Moving Average | 15.35 USD |
CGEM Share Statistics
| Avg. Volume (3 month) | 842.91K USD |
| Avg. Daily Volume (10-Days) | 1.41M USD |
| Shares Outstanding | 64.35M |
| Float | 48.09M |
| Short Ratio | 12.27 |
| % Held by Insiders | 0.42% |
| % Held by Institutions | 112.63% |
| Shares Short | 9.63M |
| Short % of Float | 20.83% |
| Short % of Shares Outstanding | 14.96% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -31.35% |
| Return on Equity (ttm) | -50.29% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -221488992 USD |
| Net Income Avi to Common (ttm) | -208343008 USD |
| Diluted EPS (ttm) | -3.11 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 334.54M USD |
| Total Cash Per Share (mrq) | 5.2 USD |
| Total Debt (mrq) | 2.07M USD |
| Total Debt/Equity (mrq) | 0.64 USD |
| Current Ratio (mrq) | 8.417 |
| Book Value Per Share (mrq) | 5 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -159250000 USD |
| Levered Free Cash Flow (ttm) | -89228128 USD |
Profile of Cullinan Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | One Main Street |
| ZIP | 02142 |
| Phone | 617 410 4650 |
| Website | https://cullinantherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 109 |
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Q&A For Cullinan Therapeutics Stock
What is a current CGEM stock price?
Cullinan Therapeutics CGEM stock price today per share is 17.15 USD.
How to purchase Cullinan Therapeutics stock?
You can buy CGEM shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cullinan Therapeutics?
The stock symbol or ticker of Cullinan Therapeutics is CGEM.
Which industry does the Cullinan Therapeutics company belong to?
The Cullinan Therapeutics industry is Biotechnology.
How many shares does Cullinan Therapeutics have in circulation?
The max supply of Cullinan Therapeutics shares is 64.35M.
What is Cullinan Therapeutics Price to Earnings Ratio (PE Ratio)?
Cullinan Therapeutics PE Ratio is now.
What was Cullinan Therapeutics earnings per share over the trailing 12 months (TTM)?
Cullinan Therapeutics EPS is -3.11 USD over the trailing 12 months.
Which sector does the Cullinan Therapeutics company belong to?
The Cullinan Therapeutics sector is Healthcare.
Cullinan Therapeutics CGEM included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27651.87 USD — |
+0.64
|
4.29B USD — | 27613.54 USD — | 27722.75 USD — | — - | 4.29B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
13615.26 USD — |
+0.67
|
— — | 13591.13 USD — | 13647.9 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6885.31 USD — |
-1.95
|
— — | 6814.3 USD — | 7076.28 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1297.75 USD — |
-1.69
|
— — | 1285.97 USD — | 1330.32 USD — | — - | — — |
- {{ link.label }} {{link}}
